Sparfosic acid
Alternative Names: CI 882; N-phosphonacetyl-L-aspartate; N-phosphonacetyl-L-aspartic acid; NSC 224131; PALA; Sparfosate sodiumLatest Information Update: 24 Jan 2003
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Aspartate carbamoyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Hepatitis B; Respiratory syncytial virus infections
Most Recent Events
- 24 Jan 2003 Discontinued - Preclinical for Hepatitis B in Australia (unspecified route)
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 15 Nov 2000 Preclinical development for Hepatitis B in Australia (Unknown route)